Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.95 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.51 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.51 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.49 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.49 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27960798 | 0.98 | TMEM97 (0.91) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| SCHEMBL274906 | 0.98 | TMEM97 (1.00) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| Bromide SCHEMBL6337077 | 0.95 | TMEM97 (0.95) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| SCHEMBL11539730 | 0.95 | TMEM97 (0.95) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL28659483 | 0.93 | TMEM97 (0.91) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| Nitrous Acid SCHEMBL18329343 | 0.88 | TMEM97 (0.81) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| Tyramine SCHEMBL27589422 | 0.88 | TMEM97 (0.81) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| SCHEMBL579569 | 0.86 | TMEM97 (0.78) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| SCHEMBL10156581 | 0.85 | TAAR1 (0.76) | TMEM97SIGMAR1LMNAMAPTKDM4E | |
| Nitric Acid SCHEMBL18329335 | 0.85 | TMEM97 (0.75) | TMEM97SIGMAR1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130363-A1 | PEST ANT BAIT COMPOSITIONS AND METHODS | THE US SECRETARY OF AGRICULTURE (US) | 2026-05-14 | — | — | US | claimed |
| CN-114853619-B | Preparation method of N-methyltyramine hydrochloride suitable for industrial production | 神隆医药（常熟）有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-114853619-A | Preparation method of N-methyltyramine hydrochloride suitable for industrial production | 神隆医药（常熟）有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113683522-A | Preparation method of N-methyltyramine hydrochloride | 广汉市派瑞林科技有限责任公司 | 2021-11-23 | — | — | CN | claimed |
| CN-106977411-B | Synthetic method of N-methyltyramine hydrochloride | 苏州永健生物医药有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106977411-A | A kind of synthetic method of N methyltyramines hydrochloride | 苏州永健生物医药有限公司 | 2017-07-25 | — | — | CN | claimed |
| CN-103755576-A | Synthesis method of N-methyl tyramine hydrochloride | SHANGHAI XUXIN CHEMICAL CO LTD | 2014-04-30 | — | — | CN | claimed |
| US-20260130363-A1 | PEST ANT BAIT COMPOSITIONS AND METHODS | THE US SECRETARY OF AGRICULTURE (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| CN-120584960-A | Application of N-methyltyramine hydrochloride in feed for breeding animals and feed | 湖北从力生物科技有限公司 | 2025-09-05 | — | — | CN | disclosed |
| CN-120584960-A | Application of N-methyltyramine hydrochloride in feed for breeding animals and feed | 湖北从力生物科技有限公司 | 2025-09-05 | — | — | CN | disclosed |
| US-20250186600-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-114853619-B | Preparation method of N-methyltyramine hydrochloride suitable for industrial production | 神隆医药（常熟）有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | SIGMAR1 562/4885ESR1 4136/4885ESR2 4459/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | SIGMAR1 266/4885ESR1 4160/4885ESR2 3750/4885 |
| US-20260130363-A1 | PEST ANT BAIT COMPOSITIONS AND METHODS | AMY1A, STOM, PTMS | SIGMAR1 1365/4885ESR1 4351/4885ESR2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.